Specialty pharmacy's role in REMS, FDA's new drug safety program; Focus on Fampridine-SR; FDA leadership promotes scientific integrity, quality standards
Medicare’s Drug Price Negotiations Could Impact Physician Reimbursement
September 19th 2024When CMS begins negotiations for physician-administered drugs under the Inflation Reduction Act, providers, including those whose services are covered by commercial insurance, could see lowered reimbursement.
Read More